May 2019

FIRST MEDICINAL CANNABIS TRIAL TO TREAT TOURETTE’S SYNDROME BRINGS HOPE TO AUSTRALIAN PATIENTS

Chris Wright, Brisbane local who was diagnosed with Tourette’s syndrome at the age of 12 is one of the first patients recruited for the trial run by Brisbane’s Wesley Medical Research. The trial aims to assess the effects of medicinal cannabis on symptoms such as uncontrollable physical and/or verbal ticks. Read the article here.

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.

READ MORE >

What’s most important in business – purpose or profit? At ANTG we get to achieve both.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >